Investigational Drug Information for LIK066
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for LIK066?
LIK066 is an investigational drug.
There have been 12 clinical trials for LIK066.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 5th 2015.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].
There are six US patents protecting this investigational drug and eighty-one international patents.
Summary for LIK066
US Patents | 6 |
International Patents | 81 |
US Patent Applications | 26 |
WIPO Patent Applications | 34 |
Japanese Patent Applications | 6 |
Clinical Trial Progress | Phase 2 (2015-06-05) |
Vendors | 13 |
Recent Clinical Trials for LIK066
Title | Sponsor | Phase |
---|---|---|
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. | Novartis Pharmaceuticals | Phase 2 |
A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity | Novartis Pharmaceuticals | Phase 2 |
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for LIK066
Top disease conditions for LIK066
Top clinical trial sponsors for LIK066
US Patents for LIK066
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
LIK066 | See Plans and Pricing | C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof | YOUNGENE THERAPEUTICS CO., LTD (China (Shanghai) Pilot Free Trade Zone, CN) | See Plans and Pricing |
LIK066 | See Plans and Pricing | Glycoside derivatives and uses thereof | Novartis AG (Basel, CH) | See Plans and Pricing |
LIK066 | See Plans and Pricing | Glycoside derivatives and uses thereof | Novartis AG (Basel, CH) | See Plans and Pricing |
LIK066 | See Plans and Pricing | Glycoside derivatives and uses thereof | Novartis AG (Basel, CH) | See Plans and Pricing |
LIK066 | See Plans and Pricing | Glycoside derivatives and uses thereof | Novartis AG (Basel, CH) | See Plans and Pricing |
LIK066 | See Plans and Pricing | Glycoside derivatives and uses thereof | Novartis AG (Basel, CH) | See Plans and Pricing |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LIK066
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
LIK066 | Australia | AU2014317663 | 2033-09-09 | See Plans and Pricing |
LIK066 | Canada | CA2923522 | 2033-09-09 | See Plans and Pricing |
LIK066 | China | CN105518014 | 2033-09-09 | See Plans and Pricing |
LIK066 | China | CN107311992 | 2033-09-09 | See Plans and Pricing |
LIK066 | European Patent Office | EP3056507 | 2033-09-09 | See Plans and Pricing |
LIK066 | Spain | ES2828548 | 2033-09-09 | See Plans and Pricing |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |